<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01764308</url>
  </required_header>
  <id_info>
    <org_study_id>O3FA</org_study_id>
    <nct_id>NCT01764308</nct_id>
  </id_info>
  <brief_title>Effects of Omega-3 Fatty Acid Supplementation in Acne Patients</brief_title>
  <acronym>Omega-3</acronym>
  <official_title>Omega-3 Fatty Acid Supplementation in Acne Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      60 patients receiving isotretinoin and 90 subjects receiving oral antibiotic therapy will be
      recruited from the UCLA acne specialty clinic.  Subjects will be randomized in a 1:1 ratio
      to receive placebo or omega-3 1200mg twice a day for 24 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Acne Lesion Count</measure>
    <time_frame>up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>In all study patients being treated for acne, lesion counts will be assessed and evaluated for any differences between patients on omega-3 fatty acid supplementation and not on supplementation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>O3FA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omega 3 Fatty Acid 1200mg twice a day for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 tablets twice a day for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3</intervention_name>
    <description>1200mg twice a day for 24 weeks</description>
    <arm_group_label>O3FA</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Omega-3 fatty acid; fish oil supplement; alpha-linolenic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 tablets twice a day for 24 weeks</description>
    <arm_group_label>O3FA</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female above 18 years of age.

          -  Moderate to severe disease at the baseline of the study identified by their
             dermatologist.

          -  Will start treatment with systemic therapy for acne in the form of either
             isotretinoin or oral antibiotics.

          -  Patients able and willing to comply with the procedures in the study protocol.

        Exclusion Criteria:

          -  Patients with history of taking omega-3 supplements for high triglyceride levels.

          -  Patients taking medications for dyslipidemia, blood thinners, or high blood pressure
             medication.

          -  Patients with a history of adverse reaction to omega-3 fatty acid supplementation.

          -  Unwilling to give inform consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina N Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA Division of Dermatology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gail D Thames, BA</last_name>
    <phone>310-825-0453</phone>
    <email>gthames@mednet.ucla.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Califonia, Los Angeles Division of Dermatology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail D Thames, BA</last_name>
      <phone>310-825-0453</phone>
      <email>gthames@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Christina N Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jenny E Kim, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 8, 2015</lastchanged_date>
  <firstreceived_date>January 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Christina Kim, MD</investigator_full_name>
    <investigator_title>Assistant Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>acne; omega-3; isotretinoin; placebo</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
